SCHEMBL4465335

SCHEMBL4465335

Cc1c(O)cc2c(c1C)OCC1(CC1)C2O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 2/20 0.34
KIT P10721 2/20 0.34
FGFR1 P11362 2/20 0.34
SRC P12931 2/20 0.34
KDR P35968 2/20 0.34
AKT1 P31749 2/20 0.33
PDPK1 O15530 1/20 0.33
PHLPP1 O60346 1/20 0.33
ILK Q13418 1/20 0.33
KDM4E B2RXH2 3/20 0.30
MAPT P10636 3/20 0.30
HPGD P15428 3/20 0.30
RECQL P46063 3/20 0.30
TDP1 Q9NUW8 3/20 0.30
ALDH1A1 P00352 2/20 0.30
CYP3A4 P08684 2/20 0.30
G6PD P11413 2/20 0.30
HSD17B10 Q99714 2/20 0.30
L3MBTL1 Q9Y468 2/20 0.30
MAPK1 P28482 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4467585 0.94 MET (0.33) METKITFGFR1SRCKDR
SCHEMBL5316125 0.79 MET (0.30) METKITFGFR1SRCKDR
SCHEMBL4467938 0.73
SCHEMBL4467672 0.66 AKT1 (0.36) AKT1PDPK1PHLPP1ILK
SCHEMBL4475116 0.65 AKT1 (0.37) METKITFGFR1SRCKDR
SCHEMBL5263619 0.65 CYP3A4 (0.39) KDM4EMAPTHPGDALDH1A1CYP3A4
SCHEMBL4463143 0.64 AKT1 (0.34) AKT1PDPK1PHLPP1ILK
SCHEMBL5267755 0.64 AKT1 (0.34) AKT1PDPK1PHLPP1ILKMEN1
SCHEMBL4462922 0.62 AKT1 (0.37) METKITFGFR1SRCKDR
SCHEMBL4464566 0.62 AKT1 (0.36) METKITFGFR1SRCKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576094-B2 Spiro derivatives as lipoxygenase inhibitors ELI LILLY AND COMPANY (US) 2009-08-18 US disclosed
EP-1836183-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS Galileo Pharmaceuticals, Inc. (US) 2007-09-26 EP disclosed
WO-2006065686-A2 SPIRO DERIVATIVES AS LIPOXYGENASE INHIBITORS GALILEO PHARMACEUTICALS, INC. (US) 2006-06-22 WO disclosed
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors GALILEO PHARMACEUTICALS, INC. 2006-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128790-A1 Spiro derivatives as lipoxygenase inhibitors ALOX15B, ALOX5, ALOX15 MET 4860/4885KIT 4742/4885FGFR1 3822/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.